Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06369740
Other study ID # ENZ20-2024-INDIANAPOLIS
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 1, 2024
Est. completion date June 4, 2024

Study information

Verified date April 2024
Source Enzyre B.V.
Contact Waander Van Heerde, PhD
Phone +31 024 6690036
Email w.vanheerde@enzyre.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study consists of two parts. In part one, case scenario focus groups with hemophilia A patients and healthcare providers (HCPs) will be held. This parts aims to identify potential use scenarios of a point of care (POC) in vitro medical for patients with hemophilia A. The main questions it aims to answer are: - How is coagulation lab testing for patients with hemophilia A currently organized? - What is the interest and what are desired alternatives of a POC in-vitro diagnostic medical device for patients with hemophilia A? Part two of the study consists of a use scenario study in which patients with hemophilia A and HCPs will evaluate two types of non-functional mock-ups of a POC in vitro medical device. The main goal of this part is to evaluate the usability of the current prototypes of the POC device.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 102
Est. completion date June 4, 2024
Est. primary completion date June 4, 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: Patients: - With Hemophilia A diagnosis - All Hemophilia A severity categories are eligible (mild, moderate, or severe) - Aged 12 years and older - For children aged 12 through 17 their parent must provide permission by signing the informed consent form - Consider English their primary language (capable of communicating in English verbally and in writing) - Capable of giving informed consent or assent Family member(s) of patients: - Related to a patient with Hemophilia A (mild, moderate, or severe) - Aged 18 years and older - Consider English their primary language (capable of communicating in English verbally and in writing) - Capable of giving informed consent or assent Healthcare professionals: - Healthcare workers specialized in hemophilia care. (e.g. hematologists, nurse practitioners, physician assistants, nurses, and pharmacists) - Capable of giving informed consent Exclusion Criteria: Patients: - Without a diagnosis of Hemophilia A - With acquired Hemophilia A - Younger than 12 years of age - Unable to communicate in English - Incapable of giving consent or assent for themselves Specifically for the case scenario focus group - Unwilling to consent to voice recording - Participating in the use scenario part of the study Specifically for the use scenario part of the study - Unwilling to consent to video recording - Participating in the case scenario part of the study Family members: - No relation to a patient with Hemophilia A (mild, moderate, or severe) - Related to a patient with acquired Hemophilia A - Younger than 18 years of age - Unable to communicate in English - Incapable of giving consent or assent for themselves Specifically for the case scenario focus group - Unwilling to consent to voice recording - Participating in the use scenario part of the study Specifically for the use scenario part of the study - Unwilling to consent to video recording - Participating in the case scenario part of the study Healthcare professionals: - Without any prior hematological experience - Not licensed as hematologists, nurse practitioners, physician assistants, nurses or pharmacists - Unable to communicate in English - Incapable of giving their consent to participate Specifically for the case scenario part of the study • Unwilling to consent to voice recording Specifically for the use scenario part of the study • Unwilling to consent to video recording

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Case scenarios - questionnaire
Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
Case scenarios - Focus groups
Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
Use scenarios - Usability test
Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
Use scenarios - interview
The participants will be interviewed and asked for their opinions and experiences with the mock-ups.

Locations

Country Name City State
United States Indiana Hemophilia & Thrombosis Center Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Enzyre B.V. Indiana Hemophilia & Thrombosis Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Current management of Hemophilia A coagulation lab testing Themes regarding the current management of Hemophilia A coagulation lab testing One day
Primary Potential case scenarios for a point of care in-vitro diagnostic device for hemophilia A One day
Primary Usability issues of the current POC in-vitro diagnostic device prototypes Overview of identified usability issues one day
Secondary User preferences for the point of care in-vitro diagnostic device One day
Secondary Problems with current Hemophilia A coagulation monitoring One day
Secondary Potential benefits of a POC device for home use, near-patient use or in clinic use One day
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1